Siegfried Group has built one of the pharmaceutical industry's most respected integrated drug substance and drug product manufacturing platforms over more than 150 years of continuous operation. Founded in 1873 and headquartered in Zofingen, Switzerland, the company has grown from a regional chemical supplier into a global contract development and manufacturing organisation (CDMO) trusted by many of the world's leading pharmaceutical and biotech companies.
Siegfried's core proposition is its ability to handle both the synthesis of active pharmaceutical ingredients (APIs) and the subsequent formulation and fill-finish of finished dosage forms under one roof. This integrated model reduces handoffs, simplifies supply chain management for clients, and supports faster development timelines from early clinical phases through to commercial-scale production. The company works across chemical synthesis, highly potent APIs (HPAPIs), and peptide manufacturing, as well as oral solid dose, liquid, and semi-solid finished forms.
Siegfried operates a network of manufacturing sites across Europe and North America, with facilities in Switzerland, Germany, France, Spain, Malta, the United States, and China. This geographic spread gives pharmaceutical clients flexible sourcing options and regulatory coverage across the major markets, including FDA, EMA, and Swissmedic-regulated sites. The company is listed on the SIX Swiss Exchange under the ticker SFZN, reflecting its standing as one of the leading publicly traded CDMOs in Europe.
The group serves innovator and generic pharmaceutical companies alike, supporting products across a range of therapy areas including central nervous system, cardiovascular, anti-infective, and oncology. Siegfried has expanded its footprint substantially through acquisitions in recent years, adding capacity and technical capabilities that complement its long-established Swiss heritage in chemical manufacturing.
Further information is available at siegfried.ch.